Pstx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pstx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pstx Today - Breaking & Trending Today

Head-To-Head Comparison: Poseida Therapeutics (NASDAQ:PSTX) versus AIM ImmunoTech (NYSE:AIM)

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Valuation and Earnings This table compares Poseida […] ....

United States , San Diego , Roche Ltd , Immunotech Inc , Poseida Therapeutics Inc , Roche Inc , Polysciences Inc , Takeda Pharmaceuticals United States Inc , Pharmaceutics International Inc , Amarex Clinical Research , Hemispherx Biopharma Inc , Poseida Therapeutics , Get Free Report , Given Poseida Therapeutic , Takeda Pharmaceuticals United States , Hoffmann La Roche , Tech Inc , Alferonn Injection , Cagliari Dipartimento , Hemispherx Biopharma , Poseida Therapeutics Daily , Nasdaq Pstx , Stock Comparison , Stock Analysis ,

Poseida Therapeutics (NASDAQ:PSTX) Price Target Raised to $20.00

Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its target price upped by HC Wainwright from $15.00 to $20.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald […] ....

Lazard Asset Management , Cantor Fitzgerald , Poseida Therapeutics Company Profile , Poseida Therapeutics Inc , Mackenzie Financial Corp , Proshare Advisors , Allspring Global Investments Holdings , Poseida Therapeutics , Free Report , Poseida Therapeutic , Get Free Report , Share Advisors , Global Investments Holdings , Asset Management , Financial Corp , Poseida Therapeutics Daily , Nasdaq Pstx , Boost Price Target , Hc Wainwright ,

HC Wainwright Raises Poseida Therapeutics (NASDAQ:PSTX) Price Target to $20.00

Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its price objective increased by HC Wainwright from $15.00 to $20.00 in a research note released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald restated an […] ....

Susquehanna Fundamental Investments , Poseida Therapeutics Company Profile , Poseida Therapeutics Inc , Cantor Fitzgerald , Prelude Capital Management , Allspring Global Investments Holdings , Poseida Therapeutics , Free Report , Poseida Therapeutic , Get Free Report , Fundamental Investments , Capital Management , Poseida Therapeutics Daily , Nasdaq Pstx , Boost Price Target , Hc Wainwright ,

Comparing Poseida Therapeutics (NASDAQ:PSTX) and Turnstone Biologics (NASDAQ:TSBX)

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) and Turnstone Biologics (NASDAQ:TSBX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Earnings and Valuation This table compares Poseida […] ....

San Diego , United States , Poseida Therapeutics Inc , Takeda Pharmaceuticals United States Inc , Turnstone Biologics Corp , Roche Ltd , Roche Inc , Poseida Therapeutics , Get Free Report , Turnstone Biologics , Turnstone Biologic , Given Turnstone Biologic , Takeda Pharmaceuticals United States , Hoffmann La Roche , Biologics Corp , Poseida Therapeutics Daily , Nasdaq Pstx , Stock Comparison , Stock Analysis ,

Short Interest in Poseida Therapeutics, Inc. (NASDAQ:PSTX) Decreases By 22.1%

Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,030,000 shares, a decrease of 22.1% from the October 15th total of 3,890,000 shares. Currently, 5.7% of the company’s stock are sold short. Based on an average trading volume […] ....

Jpmorgan Chase Co , Renaissance Technologies , Charles Schwab Investment Management Inc , Cantor Fitzgerald , Poseida Therapeutics Inc , Dimensional Fund Advisors , Silverarc Capital Management , Poseida Therapeutics , Get Free Report , Fund Advisors , Schwab Investment Management , Capital Management , Poseida Therapeutics Daily , Nasdaq Pstx ,